Research programme: mRNA therapeutics - Arcturus Therapeutics/Ultragenyx Pharmaceutical

Drug Profile

Research programme: mRNA therapeutics - Arcturus Therapeutics/Ultragenyx Pharmaceutical

Latest Information Update: 21 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Arcturus Therapeutics
  • Developer Arcturus Therapeutics; Ultragenyx Pharmaceutical
  • Class RNA
  • Mechanism of Action RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 16 Mar 2016 Arcturus Therapeutics receives intent to grant notice from the European Patent Office for their unlocked nucleomonomer agent (UNA) Technology
  • 29 Oct 2015 Early research in Undefined indication in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top